Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration

Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration

BackgroundCaspofungin, the first FDA-approved echinocandin antifungal agent, plays a vital role in managing invasive fungal infections (IFIs). Despite its established efficacy, large-scale real-world safety evaluations remain limited. This study provides a comprehensive pharmacovigilance analysis of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhengfu Li, Zhiwei Cui, De Xie, Fan Zou, Chengyu Zhu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Pharmacology
Subjects:	caspofungin adverse drug events drug-induced liver injury real-world data PI3K/AKT signaling
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1632488/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predictors of caspofungin exposure-response relationship: a retrospective cohort study on therapeutic drug monitoring parameters
by: Mingwei Meng, et al.
Published: (2025-07-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study
by: Romain Arrestier, et al.
Published: (2025-07-01)

OUTCOME OF CANDIDA PARAPSILOSIS COMPLEX INFECTIONS TREATED WITH CASPOFUNGIN IN CHILDREN
by: İlker Devrim, et al.
Published: (2016-09-01)

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
by: Chengyu Zhu, et al.
Published: (2025-03-01)

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources
by: Mahboubeh Shabanzadeh, et al.
Published: (2025-07-01)

Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024)
by: Yang Yang, et al.
Published: (2025-04-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
by: Yongfu Song, et al.
Published: (2025-03-01)

Efficacy and safety of voriconazole and caspofungin for the treatment of invasive pulmonary aspergillosis in critically ill patients in China
by: Zhuo Li, et al.
Published: (2025-05-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

The GPCR antagonist PPTN synergizes with caspofungin providing increased fungicidal activity against Aspergillus fumigatus
by: Thaila Fernanda dos Reis, et al.
Published: (2025-05-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
by: Jinlong Huang, et al.
Published: (2025-04-01)

Potential adverse events of fluoxetine: a real-world study based on the FAERS database
by: Xuezheng Gao, et al.
Published: (2025-07-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system
by: Linlin Tang, et al.
Published: (2025-07-01)

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
by: Heng Chen, et al.
Published: (2024-12-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Descriptive analysis of the national drug adverse events (AEs) database in Lebanon
by: Rita Karam, et al.
Published: (2025-12-01)

Prevalence of Adverse Events and Hypoglycemia in Patients with Type 2 Diabetes Treated with Novel Antidiabetic Medications
by: Ebrahim Mohammadi, et al.
Published: (2025-03-01)

Magnitude and Characteristics of Adverse Drug Events in Saudi Arabia: A Systematic Review
by: Lina Alharbi, et al.
Published: (2025-04-01)

The Eucommia ulmoides - Achyranthes bidentata pair and their active monomers exert synergistic therapeutic potential for osteoarthritis through the PI3K-AKT pathway
by: Chun Chen, et al.
Published: (2025-08-01)

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024
by: Siyu Lou, et al.
Published: (2025-06-01)

Review of the textbook “Clinical and pharmacological characteristics of biotechnological drugs: from classifications to adverse events”
by: V. I. Petrov
Published: (2024-04-01)

Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis
by: Changhong Lu, et al.
Published: (2025-07-01)

A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
by: Jingjing Huang, et al.
Published: (2025-03-01)

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
by: Lele Ge, et al.
Published: (2025-05-01)

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
by: Hao Zhu, et al.
Published: (2025-03-01)

Caspofungin Combined With TMP/SMZ in Treatment of Intractable Acute Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients: Case Report and Literature Review
by: Hongtao Hu, et al.
Published: (2025-08-01)

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Analysis of Reporting Trends of Serious Adverse Events Associated With Anti‐Obesity Drugs
by: Branislava B. Raičević, et al.
Published: (2025-04-01)

Occurrence and predictors of adverse events associated with linezolid in the treatment of patients with drug resistant tuberculosis and their impact on treatment outcomes
by: Abhirami V, et al.
Published: (2025-06-01)

ICD-10 Codes to Identify Adverse Drug Events Associated with Antibiotics in Administrative Data
by: Hannah Lishman, et al.
Published: (2025-03-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors
by: Carly R. Cabel, et al.
Published: (2025-05-01)

Adverse events in the neonatal intensive care unit identified by triggers
by: Fabiana Bragança Albanese, et al.
Published: (2025-05-01)

Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
by: Jingkai Di, et al.
Published: (2025-07-01)